Serrano M, Hannon G, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704–7.

Article  CAS  PubMed  Google Scholar 

Kamb A, Gruis N, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264:436–40.

Article  CAS  PubMed  Google Scholar 

Robertson K, Jones P. Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus. Oncogene. 1999;18:3810–20.

Article  CAS  PubMed  Google Scholar 

Stone S, Jiang P, Dayananth P, et al. Complex structure and regulation of p16(MTS1) locus. Cancer Res. 1995;55:2988–94.

CAS  PubMed  Google Scholar 

Stott FJ, Bates S, James MC, et al. The alternative product from the human CDKN2A locus, p16(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998;17:5001–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet. 1994;8:15–21.

Article  CAS  PubMed  Google Scholar 

Kannengiesser C, Brookes S, del Arroyo AG, et al. Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients. Hum Mutat. 2009;30:564–74.

Article  CAS  PubMed  Google Scholar 

Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463:899–905.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen S, Sanjana NE, Zheng K, et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell. 2015;160(6):1246–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cui C, Gan Y, Gu L, et al. P16-specific DNA methylation by engineered zinc finger methyltransferase inactivates gene transcription and promotes cancer metastasis. Genome Biol. 2015;16:252.

Article  PubMed  PubMed Central  Google Scholar 

Zhang X, Li P, Gan Y, et al. Driving effect of P16 methylation on telomerase reverse transcriptase-mediated immortalization and transformation of normal human fibroblasts. Chin Med J Engl. 2024. https://doi.org/10.1097/CM9.0000000000003004.

Article  PubMed  PubMed Central  Google Scholar 

Qiao JL, Tian Y, Cheng XJ, et al. CDKN2A deletion leading to hematogenous metastasis of human gastric carcinoma. Front Oncol. 2021;11: 801219.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fan ZY, Zhou J, Tian Y, et al. Somatic CDKN2A copy number variations are associated with the prognosis of esophageal squamous cell dysplasia. Chin Med J. 2024. https://doi.org/10.1097/CM9.0000000000002982.

Article  PubMed  PubMed Central  Google Scholar 

Braun M, Pastorczak A, Fendler W, et al. Biallelic loss of CDKN2A is associated with poor response to treatment in pediatric acute lymphoblastic leukemia. Leuk Lymphoma. 2017;58:1162–71.

Article  CAS  PubMed  Google Scholar 

Zhang J, Bu X, Wang H, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2018;553:91–5.

Article  CAS  PubMed  Google Scholar 

Yu J, Yan J, Guo Q, et al. Genetic aberrations in the CDK4 pathway are associated with innate resistance to PD-1 blockade in chinese patients with non-cutaneous melanoma. Clin Cancer Res. 2019;25:6511–23.

Article  CAS  PubMed  Google Scholar 

Xing R, Zhou Y, Yu J, et al. Whole-genome sequencing reveals novel tandem-duplication hotspots and a prognostic mutational signature in gastric cancer. Nat Commun. 2019;10:2037.

Article  PubMed  PubMed Central  Google Scholar 

Song Y, Li L, Ou Y, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509(7498):91–5.

Article  CAS  PubMed  Google Scholar 

Patel A, Schwab R, Liu YT, et al. Amplification and thrifty single-molecule sequencing of recurrent somatic structural variations. Genome Res. 2014;24:318–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tian Y, Zhou J, Qiao J, et al. Detection of somatic copy number deletion of the CDKN2A gene by quantitative multiplex PCR for clinical practice. Front Oncol. 2022;12:1038380.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kettunen E, Savukoski S, Salmenkivi K, et al. CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure. BMC Cancer. 2019;19:507.

Article  PubMed  PubMed Central  Google Scholar 

Wolter M, Felsberg J, Malzkorn B, et al. Droplet digital PCR-based analyses for robust, rapid, and sensitive molecular diagnostics of gliomas. Acta Neuropathol Commun. 2022;10:42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsuriel S, Hannes V, Hasona A, et al. Digital PCR-based method for detecting CDKN2A loss in brain tumors. Mol Diagn Ther. 2022;26:689–98.

Article  CAS  PubMed  Google Scholar 

Hindson BJ, Ness KD, Masquelier DN, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem. 2011;83:8604–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wunder JS, Eppert K, Burrow SR, Gokgoz N, Bell RS, Andrulis IL. Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas. Oncogene. 1999;18(3):783–8.

Article  CAS  PubMed  Google Scholar 

Kim B, et al. CCNE1 amplification is associated with liver metastasis in gastric carcinoma. Pathol Res Pract. 2019;215(8): 152434.

Article  CAS  PubMed  Google Scholar 

Mejia-Guerrero S, Quejada M, Gokgoz N, Gill M, Parkes RK, Wunder JS, Andrulis IL. Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma. Genes Chromosom Cancer. 2010;49(6):518–25.

Article  CAS  PubMed  Google Scholar 

Martínez-Jañez N, et al. First-line therapy with palbociclib in patients with advanced HR(+)/HER2(-) breast cancer: the real-life study PALBOSPAIN. Breast Cancer Res Treat. 2024. https://doi.org/10.1007/s10549-024-07287-w.

Article  PubMed  PubMed Central  Google Scholar 

Gounder MM, et al. A first-in-human phase i study of Milademetan, an MDM2 Inhibitor, in patients with advanced liposarcoma, solid tumors, or lymphomas. J Clin Oncol. 2023;41(9):1714–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tadesse S, Caldon EC, Tilley W, Wang S. Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update. J Med Chem. 2019;62(9):4233–51.

Article  CAS